PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC grew its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 7,021.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,409 shares of the company’s stock after acquiring an additional 6,319 shares during the period. GAMMA Investing LLC’s holdings in PROCEPT BioRobotics were worth $373,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Thematics Asset Management acquired a new position in PROCEPT BioRobotics during the 4th quarter worth $46,000. Signaturefd LLC boosted its stake in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after buying an additional 145 shares during the period. IFP Advisors Inc acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth about $58,000. Arcadia Investment Management Corp MI acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth about $64,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth approximately $207,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insider Buying and Selling

In related news, Director Antal Rohit Desai sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the transaction, the director now owns 14,363 shares of the company’s stock, valued at $883,180.87. This trade represents a 63.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 100,000 shares of company stock worth $6,271,250 in the last quarter. 6.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Morgan Stanley decreased their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Truist Financial lowered their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, April 11th. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a report on Saturday, May 24th. Finally, Bank of America decreased their price target on PROCEPT BioRobotics from $104.00 to $84.00 and set a “buy” rating for the company in a report on Friday, April 25th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.00.

PROCEPT BioRobotics Trading Up 0.9%

NASDAQ PRCT opened at $60.22 on Friday. The firm’s fifty day moving average price is $56.98 and its 200 day moving average price is $66.05. PROCEPT BioRobotics Corporation has a 12 month low of $47.04 and a 12 month high of $103.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.95 and a quick ratio of 7.75. The company has a market capitalization of $3.33 billion, a price-to-earnings ratio of -35.42 and a beta of 1.10.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 36.20% and a negative return on equity of 28.09%. The company had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. PROCEPT BioRobotics’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, sell-side analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).